Phase I Open Label Multicenter Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2013
At a glance
- Drugs ME 143 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 04 Jun 2012 Status changed from active, no longer recruiting to completed.
- 03 Apr 2012 Results will be reported at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Marshall Edwards media release.
- 03 Apr 2012 Status changed from recruiting to active, no longer recruiting, according to a Marshall Edwards media release.